374
Participants
Start Date
October 17, 2007
Primary Completion Date
February 5, 2008
Study Completion Date
February 5, 2008
MOA-728
MOA-728 will be administered per the dose and schedule specified in the arm.
Placebo
Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Jan Toorpstraat 164
Wilrijkstraat 10
Durban Kwa-Zulu
Nyíregyháza
Roosendaal
Adelaide SA
Elizabeth Vale SA
Worcester
Somerset West
Pécs
Székesfehérvár
Veszprém
De Pintelaan 185
New York
The Bronx
Albany
Syracuse
Pittsburgh
Pittsburgh
Hershey
Sellersville
Philadelphia
Philadelphia
Philadelphia
Baltimore
Winchester
Norfolk
Bergamo
Morgantown
Winston-Salem
Winston-Salem
Durham
Jacksonville
Jacksonville
Pensacola
Orlando
Melbourne
Miami
Miami
Tampa
Naples
Inverness
Padua
Nashville
Knoxville
Memphis
Jackson
Lexington
Columbus
Corso Giovecca 203
Cleveland
Cincinnati
Detroit
Flint
Des Moines
Milwaukee
Sioux Falls
Peoria
Columbia
Kansas City
Omaha
Omaha
Benton
Oklahoma City
Fort Worth
Temple
San Antonio
Denver
Denver
Albuquerque
Los Angeles
Long Beach
Colton
Loma Linda
Laguna Hills
Orange
Santa Barbara
San Jose
Portland
Bend
Bellevue
Tacoma
Boston
Boston
Springfield
Ann Arbor
New Brunswick
Stony Brook
Chapel Hill
Philadelphia
Providence
Edmonton
Vancouver
Montreal
Nussbaumstrasse 20
Augustenburger Platz 1
Heidelberg
Gemelli
Powstancow Wielkopolskich 72
Bydgoszcz
Polnocna 42
Moreletapark Pretoria
Pretoria
Pretoria Gauteng
Pretoria Gauteng
Kangnam-Gu, Seoul
Progenics Pharmaceuticals, Inc.
INDUSTRY
Bausch Health Americas, Inc.
INDUSTRY